Product Description
Chong Kun Dang was developing ckd-390, an oral drug, for the treatment of Chronic Hepatitis B (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02805738)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatitis B, Chronic|Hepatitis A
Phase 1: Hepatitis B, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02589457 |
163BE15028 | P1 |
Completed |
Hepatitis B, Chronic |
2015-12-01 |
2019-03-20 |
Treatments |
|
NCT02805738 |
163HBV15036 | P3 |
Unknown status |
Hepatitis B, Chronic|Hepatitis A |
2017-11-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|